![](https://endpts.com/wp-content/uploads/2020/08/Paul-Dabrowski-Getty-scaled.jpg)
Paul Dabrowski, Synthego CEO (Noam Galai/Getty Images for TechCrunch)
With $200M in new cash, Synthego wants to become the manufacturing bedrock for CRISPR. But where are its customers?
After nearly a decade developing CRISPR-based tools to help researchers in academia and biotech run their experiments, Synthego is getting into a new game: manufacturing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.